GB2232892A - Occlusive body for administering a physiologically active substance - Google Patents

Occlusive body for administering a physiologically active substance

Info

Publication number
GB2232892A
GB2232892A GB9014721A GB9014721A GB2232892A GB 2232892 A GB2232892 A GB 2232892A GB 9014721 A GB9014721 A GB 9014721A GB 9014721 A GB9014721 A GB 9014721A GB 2232892 A GB2232892 A GB 2232892A
Authority
GB
United Kingdom
Prior art keywords
administering
active substance
physiologically active
occlusive body
occlusive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9014721A
Other versions
GB9014721D0 (en
GB2232892B (en
Inventor
John Mark Tucker
Mark Rupert Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888804164A external-priority patent/GB8804164D0/en
Application filed by Individual filed Critical Individual
Priority to GB9014721A priority Critical patent/GB2232892B/en
Publication of GB9014721D0 publication Critical patent/GB9014721D0/en
Publication of GB2232892A publication Critical patent/GB2232892A/en
Application granted granted Critical
Publication of GB2232892B publication Critical patent/GB2232892B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
GB9014721A 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance Expired - Lifetime GB2232892B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9014721A GB2232892B (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound
GB9014721A GB2232892B (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance
PCT/GB1989/000185 WO1989007959A1 (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Publications (3)

Publication Number Publication Date
GB9014721D0 GB9014721D0 (en) 1990-10-03
GB2232892A true GB2232892A (en) 1991-01-02
GB2232892B GB2232892B (en) 1991-07-24

Family

ID=26293526

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9014721A Expired - Lifetime GB2232892B (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Country Status (1)

Country Link
GB (1) GB2232892B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2314025A (en) * 1996-06-13 1997-12-17 Anthony Clive Umfrevill Fisher Footwear deodoriser
WO1999052513A1 (en) 1998-04-14 1999-10-21 Stowic Resources Limited Method of manufacturing transdermal patches
WO2002062314A1 (en) * 2001-02-02 2002-08-15 United Pharmaceuticals Manufacturing Co. Limited Oral drug delivery system
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8343512B2 (en) 2006-09-26 2013-01-01 Infectious Disease Research Institute Treatment of allergic conditions using a composition containing synthetic adjuvant
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2015112485A1 (en) 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
WO2017200852A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
US9895435B2 (en) 2012-05-16 2018-02-20 Immune Design Corp. Vaccines for HSV-2
EP3563834A1 (en) 2012-02-07 2019-11-06 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US11739054B2 (en) 2017-06-11 2023-08-29 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4067961A (en) * 1975-03-19 1978-01-10 The Procter & Gamble Company Controlled release article
EP0186019A2 (en) * 1984-12-22 1986-07-02 Schwarz Pharma Ag Medicated dressing
EP0197504A2 (en) * 1985-04-05 1986-10-15 Merck & Co. Inc. pH-mediated drug delivery system
GB2174605A (en) * 1985-05-03 1986-11-12 Alza Corp Transdermal drug delivery
EP0208395A1 (en) * 1985-05-16 1987-01-14 Euroceltique S.A. Transdermal delivery system

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122B1 (en) * 1969-04-01 1982-11-23
US4067961A (en) * 1975-03-19 1978-01-10 The Procter & Gamble Company Controlled release article
EP0186019A2 (en) * 1984-12-22 1986-07-02 Schwarz Pharma Ag Medicated dressing
EP0197504A2 (en) * 1985-04-05 1986-10-15 Merck & Co. Inc. pH-mediated drug delivery system
GB2174605A (en) * 1985-05-03 1986-11-12 Alza Corp Transdermal drug delivery
EP0208395A1 (en) * 1985-05-16 1987-01-14 Euroceltique S.A. Transdermal delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Pharmaceutics, vol. 48, 1988, pages247-254 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2314025A (en) * 1996-06-13 1997-12-17 Anthony Clive Umfrevill Fisher Footwear deodoriser
GB2314025B (en) * 1996-06-13 2000-05-03 Anthony Clive Umfrevill Fisher Footwear deodoriser
WO1999052513A1 (en) 1998-04-14 1999-10-21 Stowic Resources Limited Method of manufacturing transdermal patches
WO2002062314A1 (en) * 2001-02-02 2002-08-15 United Pharmaceuticals Manufacturing Co. Limited Oral drug delivery system
AU2002228213B2 (en) * 2001-02-02 2006-10-26 United Pharmaceuticals Manufacturing Co. Limited Oral drug delivery system
EP3795173A1 (en) 2006-09-26 2021-03-24 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8343512B2 (en) 2006-09-26 2013-01-01 Infectious Disease Research Institute Treatment of allergic conditions using a composition containing synthetic adjuvant
US8609114B2 (en) 2006-09-26 2013-12-17 Infectious Diesease Research Institute Methods of using a vaccine composition containing synthetic adjuvant
US8840908B2 (en) 2006-09-26 2014-09-23 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9950063B2 (en) 2006-09-26 2018-04-24 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9907845B2 (en) 2006-09-26 2018-03-06 Infectious Disease Research Institute Methods of using a vaccine composition containing synthetic adjuvant
US9987355B2 (en) 2006-09-26 2018-06-05 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP3403667A1 (en) 2006-09-26 2018-11-21 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US10792359B2 (en) 2006-09-26 2020-10-06 Infectious Disease Research Institute Methods of using a vaccine composition containing synthetic adjuvant
US10765736B2 (en) 2006-09-26 2020-09-08 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP3251680A1 (en) 2008-05-22 2017-12-06 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9480740B2 (en) 2009-06-05 2016-11-01 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US9814772B2 (en) 2009-06-05 2017-11-14 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US10632191B2 (en) 2009-06-05 2020-04-28 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP3124491A1 (en) 2009-06-05 2017-02-01 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3563834A1 (en) 2012-02-07 2019-11-06 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
US9895435B2 (en) 2012-05-16 2018-02-20 Immune Design Corp. Vaccines for HSV-2
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US8962593B2 (en) 2013-04-18 2015-02-24 Immune Design Corp. GLA monotherapy for use in cancer treatment
US10342815B2 (en) 2013-04-18 2019-07-09 Immune Design Corp. GLA monotherapy for use in cancer treatment
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US10993956B2 (en) 2013-04-18 2021-05-04 Immune Design Corp. GLA monotherapy for use in cancer treatment
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015112485A1 (en) 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
WO2017200852A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
US11739054B2 (en) 2017-06-11 2023-08-29 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof

Also Published As

Publication number Publication date
GB9014721D0 (en) 1990-10-03
GB2232892B (en) 1991-07-24

Similar Documents

Publication Publication Date Title
ZA891403B (en) Occlusive body for administering a physiologically active substance
GR1002252B (en) A novel therapeutic active compound and preparation method therefore.
GB8828477D0 (en) Medical aerosol formulations
AU2550288A (en) A medical device for introduction into a body cavity
GB2232892B (en) Occlusive body for administering a physiologically active substance
AU3926589A (en) Pharmaceutical compounds exhibiting somatostatin-like activity
GR3023006T3 (en) Medicament for augmenting fetal hemoglobin
ZA898201B (en) Gestodene-containing agent for transdermal administration
EP0294053A3 (en) Physiologically active agent for agricultural use
EP0450100A4 (en) Physiologically active peptide
AU8303687A (en) Composition for administration through a body cavity
ZA899948B (en) Pharmaceutical preparation
EP0455818A4 (en) Physiologically active substance be-16627
HK37795A (en) Pharmaceutically active dithioketene derivatives
GB8802391D0 (en) Medicinal formulations
AU8640491A (en) Device for administering a physiologically active substance to the gastro-intestinal tract
GB8805811D0 (en) Pharmaceutically active compounds
IE882467L (en) Pharmaceutical preparation for external use
GB8901158D0 (en) Administering drugs
GB8914384D0 (en) A capsule for a medicament
BG48198A1 (en) Active sonorifying body
SG171194G (en) Pharmaceutically active dithioketene derivatives
GB8821120D0 (en) Therapeutic substance
GB8814742D0 (en) Medicament inhalation device
GB8809045D0 (en) Therapeutic agent

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20080223